查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018290

美國避孕藥具市場規模、佔有率和趨勢分析報告：基於產品、區域和細分市場的預測，2026-2033年

U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國避孕藥市場概況

2025 年美國避孕藥具市場價值 84 億美元，預計到 2033 年將達到 124 億美元，2026 年至 2033 年的複合年成長率為 4.9%。

現代避孕方法的普及，以及青少年和年輕人對性健康和計劃生育意識的提高，是美國市場成長的主要驅動力。

此外，政府計畫正在擴大避孕藥具的取得途徑，以預防青少年意外懷孕。以下章節概述了影響女性避孕和健康市場的關鍵市場促進因素，包括研發和發展趨勢。本文重點在於近期推出的產品、監管核准、公共衛生舉措以及技術創新，這些都拓展了避孕選擇，改善了取得途徑，並推動了美國市場的發展。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場趨勢/前景
  • 市場動態
  • 法律規範
  • 商業環境分析工具

第4章：依產品進行業務分析

  • 美國避孕藥市場：基於產品的波動分析
  • 產品特定波動分析、市佔率分析（2025 年及 2033 年）
  • 美國避孕藥市場：按產品分類的估算與預測
  • 丸
    • 平板電腦市場，2021-2033年
  • 避孕器（IUD）
    • 子宮內避孕器（IUD）市場，2021-2033年
    • 荷爾蒙型子宮內避孕器
    • 非荷爾蒙子宮內避孕器
  • 保險套
    • 2021-2033年避孕套市場
    • 男用保險套
    • 女性用保險套
  • 避孕環
    • 避孕環市場，2021-2033年
  • 皮下植入
    • 皮下植入市場，2021-2033年
  • 注射藥物
    • 注射劑市場，2021-2033年
  • 其他
    • 其他市場，2021-2033年

第5章：區域商業分析

  • 美國避孕藥市場：區域波動分析
  • 區域波動分析、市佔率分析（2025 年及 2033 年）
  • 美國避孕藥市場：區域估算與預測
  • 西
    • 西市場，2021-2033年
  • 東南部
    • 東南亞市場，2021-2033年
  • 西南
    • 西南市場，2021-2033
  • 東北
    • 東北市場，2021–2033
  • 中西部
    • 中西部市場，2021–2033 年

第6章 競爭情勢

  • 公司分類
  • 2025年公司市場分析
  • 策略規劃
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 其他
  • 公司簡介列表
    • Church & Dwight Co., Inc.
    • Reckitt Benckiser Group Plc
    • Organon Group of Companies
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • The Cooper Companies, Inc.
    • Mayer Laboratories Inc
    • Agile Therapeutics
    • Mayne Pharma Group Limited.
    • Bayer AG
    • Afaxys, Inc.
    • AbbVie
    • Gedeon Richter
Product Code: GVR-2-68038-702-5

U.S. Contraceptive Market Summary

The U.S. contraceptive market size was valued at USD 8.4 billion in 2025 and is expected to reach USD 12.4 billion by 2033, growing at a CAGR of 4.9% from 2026 to 2033. The increase in the use of modern contraceptives and the rise in awareness among adolescents and young people about sexual health and family planning are key factors driving the U.S. market growth.

Moreover, government programs have led to an increase in access to contraceptives that help prevent unwanted pregnancies in teenagers. The section below outlines key market factors such as research and development and trends shaping the women's contraceptive health market. It highlights recent product launches, regulatory approvals, public health initiatives, and technological innovations that are expanding contraceptive choices, improving accessibility, and driving market growth in the U.S.

U.S. Contraceptive Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. contraceptive market report based on product and region.

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Pills
  • Intrauterine Devices (IUD)
    • Hormonal IUD
    • Nonhormonal IUD
  • Condoms
    • Male Condoms
    • Female Condoms
  • Vaginal Ring
  • Subdermal Implants
  • Injectable
  • Others
  • Region Outlook (Revenue, USD Billion, 2021 - 2033)
  • West
  • Southeast
  • Southwest
  • Northeast
  • Midwest

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Contraceptive Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Product segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. U.S. Contraceptive Market: Product Movement Analysis
  • 4.2. U.S. Contraceptive Market: Product Segment Dashboard
  • 4.3. Product Movement & Market Share Analysis, 2025 & 2033
  • 4.4. U.S. Contraceptive Market Estimates & Forecast, by Product
  • 4.5. Pills
    • 4.5.1. Pills Market, 2021 - 2033 (USD Million)
  • 4.6. Intrauterine Devices (IUD)
    • 4.6.1. Intrauterine Devices (IUD) Market, 2021 - 2033 (USD Million)
    • 4.6.2. Hormonal IUD
      • 4.6.2.1. Hormonal IUD market, 2021 - 2033 (USD Million)
    • 4.6.3. Nonhormonal IUD
      • 4.6.3.1. Nonhormonal IUD market, 2021 - 2033 (USD Million)
  • 4.7. Condoms
    • 4.7.1. Condoms Market, 2021 - 2033 (USD Million)
    • 4.7.2. Male Condoms
      • 4.7.2.1. Male condoms market, 2021 - 2033 (USD Million)
    • 4.7.3. Female Condoms
      • 4.7.3.1. Female condoms market, 2021 - 2033 (USD Million)
  • 4.8. Vaginal Ring
    • 4.8.1. Vaginal Ring Market, 2021 - 2033 (USD Million)
  • 4.9. Subdermal Implants
    • 4.9.1. Subdermal Implants Market, 2021 - 2033 (USD Million)
  • 4.10. Injectable
    • 4.10.1. Injectable Market, 2021 - 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Region Business Analysis

  • 5.1. U.S. Contraceptive Market: Region Movement Analysis
  • 5.2. U.S. Contraceptive Market: Region Segment Dashboard
  • 5.3. Region Movement & Market Share Analysis, 2025 & 2033
  • 5.4. U.S. Contraceptive Market Estimates & Forecast, by Region
  • 5.5. West
    • 5.5.1. West Market, 2021 - 2033 (USD Million)
  • 5.6. Southeast
    • 5.6.1. Southeast Market, 2021 - 2033 (USD Million)
  • 5.7. Southwest
    • 5.7.1. Southwest Market, 2021 - 2033 (USD Million)
  • 5.8. Northeast
    • 5.8.1. Northeast Market, 2021 - 2033 (USD Million)
  • 5.9. Midwest
    • 5.9.1. Midwest Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Company Market Position Analysis, 2025
  • 6.3. Strategy Mapping
    • 6.3.1. Mergers & Acquisitions
    • 6.3.2. Partnership and Collaborations
    • 6.3.3. New Product Launch
    • 6.3.4. Others
  • 6.4. Company Profiles/Listing
    • 6.4.1. Church & Dwight Co., Inc.
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Product benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. Reckitt Benckiser Group Plc
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Product benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. Organon Group of Companies
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Product benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Pfizer, Inc.
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Product benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Teva Pharmaceutical Industries Ltd.
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Product benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. The Cooper Companies, Inc.
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Product benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Mayer Laboratories Inc
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Product benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Agile Therapeutics
      • 6.4.8.1. Overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Product benchmarking
      • 6.4.8.4. Strategic initiatives
    • 6.4.9. Mayne Pharma Group Limited.
      • 6.4.9.1. Overview
      • 6.4.9.2. Financial performance
      • 6.4.9.3. Product benchmarking
      • 6.4.9.4. Strategic initiatives
    • 6.4.10. Bayer AG
      • 6.4.10.1. Overview
      • 6.4.10.2. Financial performance
      • 6.4.10.3. Product benchmarking
      • 6.4.10.4. Strategic initiatives
    • 6.4.11. Afaxys, Inc.
      • 6.4.11.1. Overview
      • 6.4.11.2. Financial performance
      • 6.4.11.3. Product benchmarking
      • 6.4.11.4. Strategic initiatives
    • 6.4.12. AbbVie
      • 6.4.12.1. Overview
      • 6.4.12.2. Financial performance
      • 6.4.12.3. Product benchmarking
      • 6.4.12.4. Strategic initiatives
    • 6.4.13. Gedeon Richter
      • 6.4.13.1. Overview
      • 6.4.13.2. Financial performance
      • 6.4.13.3. Product benchmarking
      • 6.4.13.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Contraceptive methods and associated side effects
  • Table 4 Classification of contraceptives by the U.S. FDA
  • Table 5 States that have expanded contraceptive coverage guarantee in the Affordable Care Act
  • Table 6 Types of oral contraceptives, composition, and regimen
  • Table 7 List of intrauterine devices currently available in the U.S.
  • Table 8 Types of male condom variants
  • Table 9 US contraceptive market revenue estimates and forecast, by product, 2021 - 2033 (USD Million)
  • Table 10 US contraceptive market revenue estimates and forecast, by region, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. contraceptive market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. contraceptive market: Parent market outlook
  • Fig. 13 U.S. contraceptive market dynamics
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 U.S. contraceptive market: Porter's five forces analysis
  • Fig. 17 U.S. contraceptive market: PESTLE analysis
  • Fig. 18 U.S. contraceptive market: product segment dashboard
  • Fig. 19 U.S. contraceptive market: product market share analysis, 2024 & 2033
  • Fig. 20 Pills market, 2021 - 2033 (USD Million)
  • Fig. 21 Intrauterine Devices (IUD) market, 2021 - 2033 (USD Million)
  • Fig. 22 Hormonal IUD market, 2021 - 2033 (USD Million)
  • Fig. 23 Nonhormonal IUD market, 2021 - 2033 (USD Million)
  • Fig. 24 Condoms market, 2021 - 2033 (USD Million)
  • Fig. 25 Male condoms market, 2021 - 2033 (USD Million)
  • Fig. 26 Female condoms market, 2021 - 2033 (USD Million)
  • Fig. 27 Vaginal ring market, 2021 - 2033 (USD Million)
  • Fig. 28 Subdermal implants market, 2021 - 2033 (USD Million)
  • Fig. 29 Injectable market, 2021 - 2033 (USD Million)
  • Fig. 30 Others market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. contraceptive market: Region segment dashboard
  • Fig. 32 U.S. contraceptive market: Region market share analysis, 2025 & 2033
  • Fig. 33 Southeast market, 2021 - 2033 (USD Billion)
  • Fig. 34 West market, 2021 - 2033 (USD Billion)
  • Fig. 35 Midwest market, 2021 - 2033 (USD Billion)
  • Fig. 36 Northeast market, 2021 - 2033 (USD Billion)
  • Fig. 37 Southwest market, 2021 - 2033 (USD Billion)
  • Fig. 38 Company/competition categorization
  • Fig. 39 Company market position analysis, 2025
  • Fig. 40 U.S. contraceptive market: Strategy mapping